Altered dietary salt intake for people with chronic kidney disease

被引:130
|
作者
McMahon, Emma J. [1 ,2 ]
Campbell, Katrina L. [1 ]
Bauer, Judith D. [2 ]
Mudge, David W. [3 ]
机构
[1] Princess Alexandra Hosp, Nutr & Dietet, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Sch Human Movement & Nutr Sci, St Lucia, Qld, Australia
[3] Univ Queensland, Princess Alexandra Hosp, Dept Nephrol, Woolloongabba, Qld, Australia
关键词
URINARY ALBUMIN EXCRETION; STAGE RENAL-DISEASE; BLOOD-PRESSURE; SODIUM-RESTRICTION; ANTIPROTEINURIC THERAPY; HEMODIALYSIS-PATIENTS; RANDOMIZED-TRIAL; SELF-EFFICACY; NITRIC-OXIDE; HYPERTENSION;
D O I
10.1002/14651858.CD010070.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Salt intake shows great promise as a modifiable risk factor for reducing heart disease incidence and delaying kidney function decline in people with chronic kidney disease (CKD). However, a clear consensus of the benefits of reducing salt in people with CKD is lacking. Objectives This review evaluated the benefits and harms of altering dietary salt intake in people with CKD. Search methods We searched the Cochrane Renal Group's Specialised Register to 13 January 2015 through contact with the Trials' Search Co-ordinator using search terms relevant to this review. Selection criteria We included randomised controlled trials (RCTs) that compared two or more levels of salt intake in people with any stage of CKD. Data collection and analysis Two authors independently assessed studies for eligibility and conducted risk of bias evaluation. Results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes, and mean difference (MD) and 95% CI for continuous outcomes. Mean effect sizes were calculated using the random-effects models. Main results We included eight studies (24 reports, 258 participants). Because duration of the included studies was too short (1 to 26 weeks) to test the effect of salt restriction on endpoints such as mortality, cardiovascular events or CKD progression, changes in salt intake on blood pressure and other secondary risk factors were applied. Three studies were parallel RCTs and five were cross-over studies. Selection bias was low in five studies and unclear in three. Performance and detection biases were low in two studies and unclear in six. Attrition and reporting biases were low in four studies and unclear in four. One study had the potential for high carryover effect; three had high risk of bias from baseline characteristics (change of medication or diet) and two studies were industry funded. There was a significant reduction in 24 hour sodium excretion associated with low salt interventions (range 52 to 141 mmol) (8 studies, 258 participants: MD-105.86 mmol/d, 95% CI-119.20 to -92.51; I-2 = 51%). Reducing salt intake significantly reduced systolic blood pressure (8 studies, 258 participants: MD-8.75 mm Hg, 95% CI-11.33 to -6.16; I-2 = 0%) and diastolic blood pressure (8 studies, 258 participants: MD-3.70 mm Hg, 95% CI-5.09 to -2.30; I-2 = 0%). One study reported restricting salt intake reduced the risk of oedema by 56%. Salt restriction significantly increased plasma renin activity (2 studies, 71 participants: MD 1.08 ng/mL/h, 95% CI 0.51 to 1.65; I-2 = 0%) and serum aldosterone (2 studies, 71 participants: 6.20 ng/dL (95% CI 3.82 to 8.58; I-2 = 0%). Antihypertensive medication dosage was significantly reduced with a low salt diet (2 studies, 52 participants): RR 5.48, 95% CI 1.27 to 23.66; I-2 = 0%). There was no significant difference in eGFR (2 studies, 68 participants: MD-1.14 mL/min/1.73 m(2),95% CI-4.38 to 2.11; I 2 = 0%), creatinine clearance (3 studies, 85 participants): MD-4.60 mL/min, 95% CI-11.78 to 2.57; I-2 = 0%), serum creatinine (5 studies, 151 participants: MD 5.14 mu mol/L, 95% CI-8.98 to 19.26; I-2 = 59%) or body weight (5 studies, 139 participants: MD -1.46 kg; 95% CI-4.55 to 1.64; I-2 = 0%). There was no significant change in total cholesterol in relation to salt restriction (3 studies, 105 participants: MD -0.23 mmol/L, 95% CI -0.57 to 0.10; I-2 = 0%) or symptomatic hypotension (2 studies, 72 participants: RR 6.60, 95% CI 0.77 to 56.55; I-2 = 0%). Salt restriction significantly reduced urinary protein excretion in all studies that reported proteinuria as an outcome, however data could not be meta-analysed. Authors' conclusions We found a critical evidence gap in long-term effects of salt restriction in people with CKD that meant we were unable to determine the direct effects of sodium restriction on primary endpoints such as mortality and progression to end-stage kidney disease (ESKD). We found that salt reduction in people with CKD reduced blood pressure considerably and consistently reduced proteinuria. If such reductions could be maintained long-term, this effect may translate to clinically significant reductions in ESKD incidence and cardiovascular events. Research into the long-term effects of sodium-restricted diet for people with CKD is warranted, as is investigation into adherence to a low salt diet.
引用
收藏
页数:68
相关论文
共 50 条
  • [41] Association between Dietary Fat Intake and Hyperuricemia in Men with Chronic Kidney Disease
    Oku, Fumika
    Hara, Akinori
    Tsujiguchi, Hiromasa
    Suzuki, Keita
    Pham, Kim-Oanh
    Suzuki, Fumihiko
    Miyagi, Sakae
    Nakamura, Masaharu
    Takazawa, Chie
    Sato, Kuniko
    Yanagisawa, Toru
    Kannon, Takayuki
    Tajima, Atsushi
    Nakamura, Hiroyuki
    NUTRIENTS, 2022, 14 (13)
  • [42] Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?
    Ramos, Christiane, I
    Gonzalez-Ortiz, Ailema
    Espinosa-Cuevas, Angeles
    Avesani, Carla M.
    Carrero, Juan Jesus
    Cuppari, Lilian
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (11) : 2049 - 2057
  • [43] A Prospective Study of Dietary Meat Intake and Risk of Incident Chronic Kidney Disease
    Mirmiran, Parvin
    Yuzbashian, Emad
    Aghayan, Maryam
    Mahdavi, Maryam
    Asghari, Golaleh
    Azizi, Fereidoun
    JOURNAL OF RENAL NUTRITION, 2020, 30 (02) : 111 - 118
  • [44] Dietary vitamin E and tocopherol isoform intake and the progression of chronic kidney disease
    Zhang, Yanjun
    Ye, Ziliang
    Zhang, Yuanyuan
    Yang, Sisi
    Gan, Xiaoqin
    Huang, Yu
    Xiang, Hao
    Wu, Yiting
    Zhang, Yiwei
    Qin, Xianhui
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025,
  • [45] Dietary Intake and Chronic Disease Prevention
    Noce, Annalisa
    Romani, Annalisa
    Bernini, Roberta
    NUTRIENTS, 2021, 13 (04)
  • [46] Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial
    Sigrist, Mhairi
    Tang, Mila
    Beaulieu, Monica
    Espino-Hernandez, Gabriella
    Er, Lee
    Djurdjev, Ognjenka
    Levin, Adeera
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (01) : 161 - 169
  • [47] Dietary salt intake activates MAP kinases in the rat kidney
    Ying, WZ
    Sanders, PW
    FASEB JOURNAL, 2002, 16 (10): : 1683 - +
  • [48] Is Dietary Salt Intake Associated With Future Impairment of Kidney Function?
    Nonaka, Daishi
    Takase, Hiroyuki
    Machii, Masashi
    Ohno, Kazuto
    Sugiura, Tomonori
    Ohte, Nobuyuki
    Dohi, Yasuaki
    CIRCULATION, 2017, 136
  • [49] Estimation of salt intake from spot urine samples in patients with chronic kidney disease
    Ogura, Makoto
    Kimura, Ai
    Takane, Koki
    Nakao, Masatsugu
    Hamaguchi, Akihiko
    Terawaki, Hiroyuki
    Hosoya, Tatsuo
    BMC NEPHROLOGY, 2012, 13
  • [50] Estimation of salt intake from spot urine samples in patients with chronic kidney disease
    Makoto Ogura
    Ai Kimura
    Koki Takane
    Masatsugu Nakao
    Akihiko Hamaguchi
    Hiroyuki Terawaki
    Tatsuo Hosoya
    BMC Nephrology, 13